Planta Medica · 2008 · 74 citations · 0 references
MedicineMedicinal ChemistryPharmacologyBiochemical PharmacologyDrug MetabolismExperimental PharmacologyAnthelmintic PharmacologyAntiparasitic PharmacologyAntiparasitic PharmacotherapyIn Vitro PharmacologyAntileishmanial TreatmentFlavonoid GlycosidesFlavonoid MetabolismLeishmaniasis Of The SkinLeishmaniasis PathogenesisMurine ModelsParasite Load AccumulationTreatment Of Leishmaniasis
Leishmaniasis is a parasitic disease that threatens 350 million people worldwide. In a search for new antileishmanial drugs, the in vitro activity of flavonoids from Kalanchoe pinnata (Crassulaceae) was previously demonstrated in infected cells. In order to demonstrate the safety and oral activity of K. pinnata, flavonoids were evaluated in vivo in a murine model of cutaneous leishmaniasis. Daily oral doses of quercetin 3-O-alpha-L-arabinopyranosyl (1-->2)-alpha-L-rhamnopyranoside, quercetin 3-O-alpha-L-rhamnopyranoside, and free quercetin (16 mg/kg body weight) all were able to control the lesion growth caused by Leishmania amazonensis and to significantly reduce parasite load. These flavonoids were as effective as the crude K. pinnata aqueous extract given at 320 mg/kg body weight. HPLC-DAD-MS analysis of the plasma of extract-treated mice suggested that quercetin and quercetin glucuronides are the main metabolites of K. pinnata quercetin glycosides. Our results indicate that K. pinnata quercetin glycosides are important active components of the aqueous extract and that they possess potent oral efficacy against cutaneous leishmaniasis.